WEDNESDAY, April 6 (HealthDay News) -- By giving more intensive
chemotherapy along with drugs designed to boost the body's own
immune system, researchers were able to roughly double survival
time for patients with advanced, metastatic colorectal cancer
compared to patients receiving standard chemotherapy alone.
In fact, the trial, results of which are being presented at the
annual meeting of the American Association for Cancer Research in
Orlando, was stopped early because of the promising findings.
"With this study, we have produced for the first time strong proof-of-concept that chemo-immunotherapy may be active and more efficacious than standard [chemotherapy] in metastatic colon cancer patients," said study lead author Dr. Pierpaolo Correale, an oncologist with Siena University School of Medicine in Siena, Italy.
The standard of care right now for patients with colorectal
cancer that's spread to other regions is to use one of two
dual-drug combinations of chemotherapy alone, or use them alongside
a newly developed monoclonal antibody treatment such as Avastin
(bevacizumab) or Erbitux (cetuximab). These approaches can boost
overall survival to about 20 to 22 months.
For this study, the research team randomized 130 patients to
receive either chemotherapy alone (with a regimen known as FOLFOX)
or to receive FOLFOX plus drugs to ramp up the immune system (this
regimen is known as GOLFIG).
The chemo/immune boost approach involves first giving patients
gemcitabine plus standard FOLFOX chemotherapy (oxaliplatin,
levofolinic acid and 5-FU/GOLF) that targets and kills the cancer
cells in a number of ways -- all the while sending off signals
alerting the immune system to the cancer.
This is then followed up with the administration of signaling
molecules called cytokines that spur key immune cells into action.
Another immune-boosting cancer drug, called aldesleukine, is also
given to help boost the population of immune cells targeted against
At the time of data collection, the patients treated with this
approach have survived an average 16.5 months without a relapse,
compared with just 7.5 months in the chemo-only group.
But the study began in 2005, before the advent of drugs like
Avastin or Erbitux, meaning that investigators do not yet know if
GOLFIG would outperform regimens that include those medications.
This needs to be looked at, said Correale.
On the other hand, many patients do not see a benefit from
biological agents such as Erbitux or Avastin because they have the
wrong genetic profile, noted one outside expert.
"Essentially, we have a very problematic subset of patients with metastatic colorectal cancer which are limited to two lines of chemotherapy and [perhaps] one biological agent," said Dr. Igor Astsaturov, assistant professor of medical oncology at the Fox Chase Cancer Center in Philadelphia.
"For those patients, which are about one-third of the overall patient population, this [new finding] will be particularly welcome news," Astsaturov said, while adding the caution that the results are still preliminary.
However, clinical use of the protocol may be delayed further by
the fact that "there is no direct commercial interest of
pharmaceutical companies," noted Correale, who is nevertheless
planning larger trials.
The costs associated with GOLFIG, he added, are "four-to-five
times lower than that produced by the current use of Avastin or
Erbitux with apparently similar therapeutic results."
Because this study was presented at a medical meeting, the
findings should be viewed as preliminary until they are published
in a peer-reviewed journal.
There's more on colorectal cancer at the
U.S. National Cancer Institute.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.